Quick Take
Harmony Biosciences Holdings (HRMY) intends to raise $100 million from the sale of its common stock in an IPO, according to an amended registration statement.
The company is advancing development and commercialization of narcolepsy and related treatments.
HRMY has shown a strong recent revenue ramp for its first product and is in further development to expand its TAM to other related indications.
It is difficult to ascertain whether its proposed $1.9 billion enterprise value at IPO is reasonable or expensive, so I'll pass on the IPO.
Company & Technology
Plymouth Meeting,